These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23437092)

  • 21. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
    Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
    J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
    Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
    BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
    Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
    Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
    Johnson J; Somerfield W; Johnson SR
    Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S; Roberds SL; Nakagawa J; Beresford E
    Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
    Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
    PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ
    J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K; Gaedeke J
    Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
    Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
    Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus.
    Zonnenberg BA; Neary MP; Duh MS; Ionescu-Ittu R; Fortier J; Vekeman F
    PLoS One; 2018; 13(11):e0204646. PubMed ID: 30439947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density.
    Hatano T; Atsuta M; Inaba H; Endo K; Egawa S
    Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
    Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
    Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
    Song X; Said Q; Tran O; Krueger DA; Bissler J
    Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
    Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
    J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.
    Young LR; Vandyke R; Gulleman PM; Inoue Y; Brown KK; Schmidt LS; Linehan WM; Hajjar F; Kinder BW; Trapnell BC; Bissler JJ; Franz DN; McCormack FX
    Chest; 2010 Sep; 138(3):674-81. PubMed ID: 20382711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.
    Kingswood JC; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D' Amato L; d'Augères GB; de Vries PJ; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC
    Nephrol Dial Transplant; 2019 Mar; 34(3):502-508. PubMed ID: 29697822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J; Parkhitko AA; Henske EP
    Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis.
    Feng Y; Mischler WJ; Gurung AC; Kavanagh TR; Androsov G; Sadow PM; Herbert ZT; Priolo C
    Cancer Res; 2020 Jul; 80(13):2751-2763. PubMed ID: 32393662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.